APONTIS PHARMA continues to gear organization towards growth and internationalization – Renowned industry expert leads supply chain management
EQS-News: APONTIS PHARMA AG
/ Key word(s): Personnel
APONTIS PHARMA continues to gear organization towards growth and internationalization – Renowned industry expert leads supply chain management
Since 3 June 2024, Mila Brückel has been responsible for all aspects of supply chain management at APONTIS PHARMA, including demand forecasting, procurement, inventory management, new product launches, and distribution to customers. In her new role, she reports directly to CEO Bruno Wohlschlegel. Mila Brückel has more than 25 years of experience in supply chain management – including 15 years in the pharmaceutical sector – and joins APONTIS PHARMA from Merck Healthcare, the healthcare segment of Merck KGaA, a leading global pharmaceutical and chemical company. There she was Head of Supply Chain for the German pharmaceutical business and before that responsible for the global supply chain of General Medicine Classics and diabetes products, among other things. Prior to Merck Healthcare, Mila Brückel was responsible for the supply chain at Airwell Germany. Information on upcoming events can be found at https://apontis-pharma.de/en/financial-calendar and the latest analyst assessments at https://apontis-pharma.de/en/share-price. APONTIS PHARMA AG is a leading pharmaceutical company specializing in Single Pill combinations in Germany. Single Pills combine two to three generic active ingredients in a single dosage form administered once a day. Single Pill therapies have been scientifically proven to significantly increase adherence and thus improve the treatment prognosis and quality of life of patients while reducing complications, mortality, and treatment costs. Consequently, Single Pill combinations are the preferred treatment option in numerous international treatment guidelines, including in the EU and Germany. APONTIS PHARMA has been developing, promoting, and distributing a broad portfolio of Single Pill combinations and other pharmaceutical products since 2013, with a special focus on cardiovascular diseases such as hypertension, hyperlipidemia, and secondary prevention. For additional information about APONTIS PHARMA, please visit www.apontis-pharma.de. Investor Relations CROSS ALLIANCE communication GmbH
04.06.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG. |
Language: | English |
Company: | APONTIS PHARMA AG |
Alfred-Nobel-Str. 10 | |
40789 Monheim | |
Germany | |
E-mail: | ir@apontis-pharma.de |
Internet: | https://apontis-pharma.de/ |
ISIN: | DE000A3CMGM5 |
WKN: | A3CMGM |
Listed: | Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt (Scale), Munich, Stuttgart, Tradegate Exchange |
EQS News ID: | 1916507 |
End of News | EQS News Service |
Editor Details
-
Company:
- EQS Newsfeed
- Website: